✦ LIBER ✦

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

✍ Scribed by Fatima Cardoso; Jean-Luc Canon; Dino Amadori; Daniela Aldrighetti; Jean-Pascal Machiels; Yasmina Bouko; Lev Verkh; Tiziana Usari; Kenneth A. Kern; Carla Giorgetti; Luc Dirix

Book ID: 119210904
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 383 KB
Volume: 21
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2012.09.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

2108 POSTER Cardiac safety of trastuzuma

2108 POSTER Cardiac safety of trastuzumab in combination with epirubicin/ cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer

✍ M. Untch; S. Tjulandin; W. Jonat; H. Meerpohl; M. Lichinitser; G.M. Manikhas; F. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase II study of gefitinib in combinati

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

✍ Ciardiello, F; Troiani, T; Caputo, F; De Laurentiis, M; Tortora, G; Palmieri, G; 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 106 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

A multicentre Phase II study of non-pegy

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

✍ M. Venturini; C. Bighin; F. Puglisi; N. Olmeo; E. Aitini; G. Colucci; O. Garrone 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 262 KB

2132 POSTER Economic impact of adding ca

2132 POSTER Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer

✍ A. Bonetti; A. Santoro; P. Ducournau; A. Cirrincione; G. Giuliani; R. Bell 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB